Baric Transcribed Interview (Redacted) — page 30

DC.Scheduling@LexitasLegal.com MS. SALAZAR: But there was a structure. DR. BARIC: There certainly was a structure. They reviewed it, responded, and then asked for responses from me, and then I gave those responses. MS. SALAZAR: And could you tell us a little bit about, at the time, what that process was like, in terms of the P3CO process? DR. BARIC: So in, was it, October 2014, the Obama administration put out the pause. The pause effectively was set up two ways. One way was that if a grant was submitted that had the potential for gain-of-function research it would be reviewed before they funded it. And the second class was if you were already doing P3, or research that might fall under the category, you had the option to either pause it voluntarily or continue it. And in the case of SHC014-WIV work, we paused it voluntarily. The third category was waivers. And so the NIH approved three groups, to my knowledge, to continue to develop a MERS coronavirus mouse model for countermeasured studies. MS. SALAZAR: And you were one of them? DR. BARIC: And we were one of them. MS. SALAZAR: Do you know who the others were? DR. BARIC: I think one group was out of the University of Utah. I can't remember the fellow's name. MS. SALAZAR: Were they individual exemptions, or was